City News: Halfords, Bovis, Superdry & Astrazeneca


Dispensations in the FTSE 250 bikes and auto rts retailer fell 23¾p to 320p as it poled a 12.1 per cent fall in pre-tax profit to £40.8 million on 6.3 per cent gamy revenue of £567.3 million.

It took a £6 million currency hit and responded to heavier omitting by rivals with a “20 per cent off all bikes” promotion.

Warmer ill and Team GB’s Olympics success pumped up cycle sales by 4 per cent, while reduced in price on the markets of car maintenance products and services were up 1.8 per cent.


BOVIS Homes clouted it is on track for record annual sales as the Government’s Help to Buy scheme and tight-fisted mortgage deals stimulate demand from house-hunters.

The FTSE 250 builder remarked trading had followed a “normal ttern” a rt from a few weeks after the EU referendum.

It wants volume growth of more than 5 per cent to over 4,000 homes, offered at an average price up 10 per cent on the previous year to about £255,000.

Chief directorate David Ritchie said: “The backdrop for housebuilding in the UK continues to be positive with insist for new homes running ahead of housing supply.”


OVERSEAS ex nsion and new spheres, including a collaboration with actor Idris Elba, helped Supergroup the rage a bumper rise in sales.

The Superdry owner lifted half-year takings by 31.1 per cent to £334 million as it made “good progress” in China and North America, categorizing online growth and new stores in Manhattan, Philadelphia and Orlando performing suitably. Half-year profit is expected to be £20-22 million.

Chief executive Euan Sutherland reported: “Our ongoing diversification reduces our reliance on any individual market.”

Shares thrive 127p to 1574p.


ASTRAZENECA flagged healthcare changes in the US after Donald Trump’s choice victory, but warned that price pressures would remain.

The downers giant’s boss scal Soriot said: “It is reasonable to assume the vista will change. The US supports innovation and new medicines, and we hope it will traces the same. But we also believe we will have to deal with cost pressures.”

Its third-quarter revenue fell 4 per cent to £4.55 billion after oppression on its cholesterol pill Crestor from cheaper generic versions.

Leave a Reply

Your email address will not be published. Required fields are marked *